Capecitabine Product is named as an intervention in 2 current clinical trials in our China, South Korea and Taiwan registers. 1 is recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is Gilead Sciences (1). The most-studied condition is Metastatic Breast Cancer.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
NCT04263298 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer
|
Phase 3 | Recruiting | Herui Yao | China |
|
Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)
NCT04639986 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer
|
Phase 3 | Active, closed | Gilead Sciences | China, South Korea, Taiwan |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Gilead Sciences | 1 |
| Herui Yao | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in South Korea | 1 | 0 |
| Clinical trials in Taiwan | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China, South Korea and Taiwan registers name Capecitabine Product as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Gilead Sciences (1) and Herui Yao (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Capecitabine Product works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Capecitabine Product works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Capecitabine Product (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.